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Objective: To quantify the cumulative effective dose (cED) of radiation due to repeated CT and PET/CT examinations after 
curative resection of gastric cancer and to assess the lifetime attributable risk (LAR) estimates based on Biological Effects 
of Ionizing Radiation VII models.
Subjects and Methods: Patients who underwent a curative resection for gastric cancer between January 2006 and 
December 2006 and were followed-up until May 2010 were included in this study. The cED was calculated by using the 
dose-length product values and conversion factors for quantitative risk assessment of radiation exposure. cED and LAR were 
compared between early and advanced gastric cancer patients and among American Joint Committee on Cancer TNM stage 
groups (stage I, II, and III). The nonparametric Mann-Whitney U and Kruskal-Wallis tests, followed by a post-hoc analysis 
with Bonferroni adjustment, were employed as part of the statistical analysis.
Results: The overall median cED was 57.8 mSv (interquartile range [IQR], 43.9-74.7). The cED was significantly higher in 
the advanced (median, 67.0; IQR, 49.1-102.3) than in the early gastric cancer group (median, 52.3; IQR, 41.5-67.9) (p < 
0.001), and increased as the TNM stage increased. For radiation exposure, 62% of all patients received an estimated cED of 
over 50 mSv, while 11% of patients received over 100 mSv. The median LAR of cancer incidence was 0.28% (IQR, 0.20-0.40) 
and there were significant differences between the early gastric cancer and advanced gastric cancer group (p < 0.001) as 
well as among the three TNM stage groups (p = 0.015). The LAR of cancer incidence exceeded 1% in 2.4% of the patients.
Conclusion: The cED increases proportionally along with tumor stage and, even in early gastric cancer or stage I patients, 
cED is much higher than that found among the general population. Considering the very good prognosis of early gastric 
cancer after curative surgery, the cED should be considered when designing a postoperative follow-up CT protocol.
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INTRODUCTION
Although gastric cancer has decreased in incidence over 
the past few decades, it remains the fourth most common 
cancer in the world and the second most common cause 
of cancer-related deaths (1). The treatment of choice for 
gastric cancer is surgical resection, which is the curative 
treatment for gastric cancer. Recently, the technical 
development of diagnostic tools such as endoscopy or 
computed tomography (CT) and widespread application Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org 145
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of surveillance programs, especially in Korea and Japan 
where gastric cancer is particularly common, more than 
60-80% of patients are diagnosed at potentially curative 
stages and 5-year survival rates are approaching 70% for 
R0 resections (2, 3). As a result, the number of patients 
who require postoperative follow-up is rapidly increasing. 
However, guidelines for postoperative follow-up have 
not been established, and different follow-up protocols 
are used by each institution (2, 4). According to recent 
National Comprehensive Cancer Network (NCCN) guidelines, 
postoperative follow-up with medical history-taking 
and physical examinations are recommended specifically 
based on the follow-up period after surgery. However, 
recommendations for follow-up radiologic imaging only 
require that the imaging be clinically indicated, without 
any guidance regarding the follow-up period or imaging 
modalities. Presently, due to improvements in diagnostic 
performance and objectivity, most imaging follow-up is 
performed by CT with a variable follow-up interval, based 
on each institution’s strategy (2, 4). 
Public concern about radiation exposure has recently 
increased due to the rapid growth of CT use in medical 
applications, as well as nuclear catastrophes such as those 
at Chernobyl and in Japan. In 2007, the International 
Commission on Radiological Protection (ICRP) recommended 
dose limitations for occupational exposure (20 mSV 
per year) and for public exposure (1 mSv per year) (5). 
However, there are no established radiation dose limits 
for patients undergoing radiographic imaging, and risk-
benefit evaluations should be performed to establish 
such guidelines. In a large-scale dose estimation study 
in the United States, more than 70% of patients received 
doses of less than 3 mSv per year, which is equivalent 
to the background levels of natural radiation in the 
United States (6). In contrast, a long-term retrospective 
cohort study demonstrated that patients with histories of 
malignancy or active malignancies experienced much higher 
radiation exposure than patients without malignancies 
(7). Considering that about 14.9-19.5% of gastric cancer 
patients are younger than 45 years of age, with a 5-year 
overall survival rate of about 70%, and rates that reach 90% 
in stage I and II cases (3, 8), there are growing concerns 
regarding cumulative radiation exposure due to lifelong 
radiologic surveillance. Therefore, it is necessary to estimate 
the current state of radiation exposure due to repeated 
follow-up CT or PET/CT imaging in gastric cancer patients 
for the risk-benefit analysis of postoperative follow-
up imaging. Therefore, the purpose of this study was to 
quantify the cumulative effective dose (cED) from repeated 
CT and PET/CT examinations after curative resection of 
gastric cancer and to assess lifetime attributable risk based 
on the “Biological Effects of Ionizing Radiation” (BEIR) VII 
models. 
SUBJECTS AND METHODS
Study Population
This retrospective study was approved by the institutional 
review board of the Yonsei University Health System and 
the requirement of informed consent was waived. Inclusion 
criteria were as follows: (a) patients who were diagnosed 
with gastric cancer and had undergone surgery with a 
curative intent between January 2006 and December 2006, 
(b) patients who were alive through May 2010, (c), patients 
who had no evidence of tumor recurrence in clinical and 
radiologic assessment, and (d) patients who had been 
regularly followed-up until May 2010. Patients were 
considered as a “follow-up loss” if their last visit did not 
occur within the last 18 months prior to May 2010. Patients 
were usually followed up at intervals of less than 1 year, but 
some patients visited the hospital a few months later than 
their prearranged follow-up dates due to personal reasons, 
and therefore we defined 18 months as the longest interval 
of regular follow-up.
Between January 2006 and December 2006, 1124 
patients underwent curative surgery for gastric cancer 
at our institution. Among these patients, eight who had 
previous or concurrent malignancies were excluded. In 
total, 99 patients were excluded due to death during the 
follow-up period. Another 27 patients, who experienced 
tumor recurrence during follow-up, were also excluded. Of 
of the remaining 990 patients, 244 were lost to follow-up. 
An additional 87 patients were excluded because CT dose 
profile reports were not available in the picture archive 
and communication system (PACS; Centricity, GE Medical 
Systems). Twenty-one patients who received neoadjuvant 
or adjuvant radiotherapy were also excluded, because 
radiotherapy deliberately uses a very high dose (between 
20 to 50 Gy) of radiation to produce deterministic effects 
(i.e., killing tumor cells). After all, 638 patients (415 
men, 223 women; average age, 60.1 years; range, 27-89 
years) were included in our study (Fig. 1). Gastric cancer 
was pathologically confirmed by either a total gastrectomy 
(n = 194) or subtotal gastrectomy (n = 444). All patients Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org 146
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were divided into two groups according to the definitions 
proposed by the Japanese Research Society for Gastric 
Cancer as follows: early gastric cancer (EGC), defined as an 
adenocarcinoma of the stomach confined to the mucosa 
or submucosa, irrespective of lymph node involvement, as 
opposed to advanced gastric cancer (AGC), which is beyond 
the submucosa of the stomach (9). Furthermore, we divided 
patients into three groups according to TNM stage (Stage 
I, II, and III) based on the American Joint Committee on 
Cancer (AJCC) 7
th edition (1). 
Postoperative Follow-up Protocols
After curative surgery, most patients who had not 
received adjuvant chemotherapy were followed-up by 
surgeons. In our institution, the routine follow-up protocols 
after curative resection of gastric cancer include abdominal-
pelvic CT every 6 months for the first 2 years and every 12 
months for the next 3 years. A PET/CT scan was performed 
if the clinician thought that a whole body evaluation was 
needed. Routine imaging surveillance was not performed 5 
years after surgery, and CT or PET/CT was only performed 
when clinicians needed to evaluate patient symptoms and 
laboratory results. Patients (n = 77) who had received 
adjuvant chemotherapy were followed up by medical 
oncologists with more intense monitoring. CT or PET/CT 
scans were performed every 3 months for the first 6 months 
and every 6 months to assess the response. In patients who 
had been enrolled in clinical trials, the follow-up frequency 
and duration of the imaging study varied according to the 
various protocols. 
CT Effective Dose Estimates 
Dose reports from PACS for all CT scans were reviewed 
by two radiologists (a faculty member with 10 years of 
experience in abdominal radiology and a senior radiology 
resident). The numbers of CT scans per patient and dose-
length product (DLP) values per CT scan were recorded 
for all patients. CT scans that were performed for medical 
conditions unrelated to gastric cancer, such as trauma, were 
excluded.
Effective dose is used as a measure of quantitative 
risk assessment for radiation exposure. We calculated the 
effective dose of each CT examination using DLP values and 
the normalized values of conversion factors (EDLP) (abdomen-
pelvis, 0.015 mSv/mGy·cm; chest, 0.017 mSv/mGy·cm; 
and head, 0.023 mSv/mGy·cm) proposed by the European 
Guidelines on Quality Criteria in Computed Tomography (5, 
10). The formula for calculating the effective dose is as 
follows: 
Effective dose (mSv) = DLP x EDLP
According to Gunner et al. (11), the estimated effective 
dose values for PET/CT protocols followed by four different 
hospitals were nearly identical, and the average effective 
dose was 7 mSv (5.7-7.0 mSv) for PET and 25 mSv (23.7-26.4 
mSv) for PET/CT. Because dose reports for PET and PET/CT 
were not available and the PET and PET/CT protocols of our 
hospital were similar to those of the previous article, we 
assumed an average effective dose of 7 mSv for PET and 25 
mSv for PET/CT (11). cED estimates for each patient were 
calculated by summing the effective doses for all CT and 
PET/CT scans.
Estimation of Lifetime Attributable Risk 
To quantify the risks of radiation exposure, we estimated 
the lifetime attributable risk (LAR) of radiation-induced 
cancer incidence and mortality by using the Biological 
Effects of Ionizing Radiation (BEIR) VII methodology on the 
basis of the patient’s sex and age (5). BEIR VII data points 
were interpolated to the nearest integer age of exposure 
by linear interpolation. No extrapolation was performed for 
patients older than 80 years, resulting in an assigned LAR 
of zero for all exposures after 80 years of age (7).
Statistical Analysis 
Statistical analyses were performed using SPSS version 
18.0.0 (SPSS Inc., Chicago, IL, USA). Each data set was 
tested for normality by means of the Shapiro-Wilk’s test and 
by normality plots. For non-normal variables, medians are 
Fig. 1. Flow chart of patient inclusion, with reason for 
exclusion and total study population.
Previous or concurrent malignancies
other than stomach cancer (n = 8)
Death during follow-up (n = 99)
1124 patients
1116 patients
990 patients
746 patients
638 patients
(Study population)
Lost to follow-up (n = 244)
Radiotherapy (n = 21)
No available dose reports (n = 87)
Tumor recurrence during follow-up
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presented with interquartile ranges (IQR). Nonparametric 
Mann-Whitney U-tests and Kruskal-Wallis tests were used 
to compare the total CT and PET exam counts, cED, and 
LAR between groups. Chi-square and Fisher’s exact tests 
were used to compare categorical variables. We used the 
Mann-Whitney U-test with a Bonferroni correction for post 
hoc analysis. Differences with p values less than 0.05 were 
considered statistically significant.
RESULTS
Patients
Of the 638 patients, 400 patients (250 men, 150 women; 
average age, 60.2 years; range, 27-88 years) were confirmed 
to have EGC, while the remaining 238 patients (165 men, 
73 women; average age, 60.0 years; range, 27-89 years) 
were diagnosed with AGC after surgery. In terms of AJCC 
TNM staging, 445, 101, and 92 patients were assigned to 
stage I, stage II, and stage III, respectively (Table 1). There 
were no significant differences in age or sex between the 
EGC and AGC groups (p = 0.470 and p = 0.081) or among 
the three TNM stage groups (p = 0.779 and p = 0.106). The 
overall median follow-up period was 47 months (IQR, 44-50 
months). The median follow up-periods of the EGC and AGC 
groups (p = 0.729) and among the three TNM stage groups (p 
= 0.647) were not significantly different (Table 1). 
Number of Imaging Studies
A total of 3035 abdomen-pelvis CT, 68 chest CT, 2 brain 
CT, and 315 PET/CT scans were performed during the follow-
up period. Among the 638 patients, 253 (39.7%, 104 AGC 
patients and 149 EGC patients) underwent PET or PET/
CT examination at least once during the follow-up period. 
The number of total imaging studies per patient was 
significantly different between the EGC and AGC groups (p < 
0.001) and among the three TNM groups (p < 0.001) based 
on the AJCC staging system (Table 2). 
Table 1. Patient Characteristics
Total (n = 638)
Age (yrs) 60.1 (27-89)
Sex (male : female) 415 : 223
Follow-up duration (months) 47 (44-50)
EGC (n = 400) AGC (n = 238) P Value
Age (yrs) 60.2 (27-88) 60.0 (27-89) 0.470
Sex (male : female) 250 : 150 165 : 73 0.081
Follow-up duration (months) 47 (44-50) 46 (43-50) 0.729
Stage I (n = 445) Stage II (n = 101) Stage III (n = 92) P Value
Age (yrs) 60.0 (27-88) 60.5 (27-89) 60.4 (31-84) 0.779
Sex (male : female) 279 : 166 68 : 33 68 : 24 0.106
Follow-up duration (months) 47 (44-50) 47 (44-50) 46 (43-49) 0.647
Note.— EGC = early gastric cancer, AGC = advanced gastric cancer, IQR = interquartile range
Table 2. Numbers of CT and PET/CT Studies and Median Cumulative Effective Doses (cED) during Follow-up Period
Number of Imaging Studies (IQR) P Value cED (IQR), mSv P Value
Total (n = 638) 5 (4-6) 57.8 (43.9-74.7)
EGC (n = 400) 5 (4-5) < 0.001 52.3 (41.5-67.9) < 0.001
AGC (n = 238) 6 (4-8) 67.0 (49.1-102.3)
Stage I (n = 445) 5 (4-5) < 0.001* 52.6 (41.7-68.0) < 0.001
†
Stage II (n = 101) 5 (4-7) 59.0 (47.4-96.0)
Stage III (n = 92) 7 (6-9) 85.5 (57.2-124.1)
Note.— *Mann-Whitney U-test with Bonferroni correction: between stage I and II, p < 0.001; between stage II and III, p < 0.001; 
and between stage I and III: p <0.001, 
†Mann-Whitney U-test with Bonferroni correction: between stage I and II, p < 0.001; 
between stage II and III, p = 0.003; and between stage I and III, p < 0.001. cED = cumulative effective dose, IQR = interquartile 
rangeKorean J Radiol 13(2), Mar/Apr 2012 kjronline.org 148
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cED Estimation 
The median cED was 57.8 mSv (IQR, 43.9-74.7) per person 
in all patients. The median cED was 52.3 mSv (IQR, 41.5-
67.9) for the EGC group and 67.0 mSv (IQR, 49.1-102.3) 
for the AGC group, and this difference was significant (p < 
0.001). For TNM staging, the median cED was significantly 
different among the three groups (p < 0.001) (Table 2). 
For the post hoc analysis, the median cED was significantly 
different between stage I and stage II (p < 0.001), between 
stage II and stage III (p < 0.001), and between stage I and 
stage III (p = 0.003) (Table 2).
Among the 638 patients followed, 69 (10.8%) received an 
estimated cED of over 100 mSv and 328 (51.4%) received 
between 50 to 100 mSv during the follow-up period (Fig. 
2) (Table 3). The remaining 241 patients (37.8%) received 
an estimated cED of < 50 mSv. In patients who received 
an estimated cED of over 100 mSv, there were significant 
differences in the median cED between the EGC and AGC 
groups (p = 0.033) and among three TNM stages (p < 0.001). 
For the post hoc analysis, stage I and stage II (p < 0.001) 
and stage I and stage III (p < 0.001) showed significant 
differences, but there was no difference between stage 
II and stage III (p = 0.096). In patients who received 
an estimated cED between 50 to 100 mSv, there were no 
significant differences among the three TNM stage groups (p 
= 0.228). 
Estimates of LAR
The median estimated LAR of cancer incidence among all 
638 patients was 0.28% (IQR: 0.20-0.40). Fifteen (2.4%) of 
the 638 patients (all AGC patients) had LARs in excess of 1%, 
and only one AGC patient exceeded 2% during the follow-up 
period after surgery. The estimates of LAR for both cancer 
incidence and mortality were higher in the AGC group than 
in the EGC group (p < 0.001 and p < 0.001, respectively) 
and increased with higher TNM stage (p < 0.001) (Table 4).
DISCUSSION
Our findings show that the median cED was 57.8 mSv over 
Fig. 2. Histogram of cumulative CT effective dose per patient. Inset includes expanded y-axis to display right tail and contains 
number of patients who received more than 100 mSv.
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Table 3. Patients with Median Cumulative Effective Doses (cED) over 50 mSv/100 mSv by CT and PET/CT
No. of Patients
Median cED
50–100 mSv (%) P Value > 100 mSv (%) P Value
Total (638)  328 (51.4) 69 (10.8)
EGC (400) 218 (54.5) 0.033 6 (1.5) < 0.001
AGC (238) 110 (46.2) 63 (26.4)
Stage I (445) 238 (53.5) 0.228 12 (2.7) < 0.001*
Stage II (101) 47 (46.5) 23 (22.8)
Stage III (92) 43 (46.7) 35 (38.0)
Note.— *Chi-square and Fisher’s exact test, followed by post hoc analysis with Bonferroni correction: between stage I and 
II, p < 0.001; between stage II and III, p = 0.096; and between stage I and III, p < 0.001. cED = cumulative effective dose Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org 149
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the course of 47 months of the postoperative follow-up 
period in patients with gastric cancer and who underwent 
gastrectomy with curative intent. Furthermore, patients 
with AGC and patients with advanced TNM stage gastric 
cancer received greater radiation doses than patients with 
EGC or less advanced stage gastric cancer during the follow-
up period. The median cumulative dose was higher than 
50 mSv in 328 (51.4%) and 100 mSv in 69 (10.8%) of 638 
patients. 
The overall median cumulative dose might be dependent 
on the proportion of EGC and AGC as well as the follow-
up protocol after a curative intent gastrectomy. Hence, the 
median cED estimated in our study could not be applied 
directly to other institutions or countries. For example, 
the proportion of EGC is relatively higher in Korea than in 
Western countries because of the widespread surveillance 
program for gastric cancer. Thus, the overall medial 
cumulative dose might be higher in Western countries 
than in Korea (12). Nevertheless, our results showed that 
cED increased with higher tumor stage and that cED was 
much higher, even in stage I or patients with EGC than in 
the normal population. This result could be the basis for 
determining the follow-up protocol in the future.
Berrington de Gonzalez stated that the cumulative 
cancer risk to the average 75-year-old patient attributable 
to diagnostic imaging was 3.2% in Japan and 1.5% in 
Germany and that, among diagnostic imaging modalities, 
CT scans were responsible for the most radiation exposure 
(13). Brenner et al. (14) reported that about 1.5 to 2.0% 
of all cancers might be attributable to the widespread use 
of CT in the United States. In our study, the overall median 
LAR was only 0.28%. However, considering that the study 
period was only 47 months and that these patients might 
undergo periodic surveillance imaging for the rest of their 
lives, the LAR may increase over their remaining lifespan. 
Furthermore, according to the BEIR VII methodology, the 
LAR of cancer incidence increases as patient age decreases 
and is higher in females than males. When the young female 
population is exposed, the probability of radiation-induced 
cancer increases because of their higher radiosensitivity 
and longer expected lifetime, making it possible for cancers 
with a long latency period to develop (5). Consequently, 
radiation exposure during postoperative follow-up should be 
monitored closely, especially in younger female patients (3, 
8, 15).
When performing CT scans, the conventional wisdom 
has been that the exposure of a patient to radiation is 
justifiable when the individual benefit outweighs the risk 
posed by the radiation. According to previous reports, 
intensive follow-ups after surgery for colorectal cancer can 
be attributed to a 5-year survival benefit (16). However, 
there is still no evidence that postoperative follow-up can 
improve overall survival in gastric cancer (2, 14, 17-19). 
Based on these results, recent NCCN guidelines recommend 
imaging studies only if clinically indicated (20). However, 
most clinicians perform regular post-operative follow-up 
due to legal issues for themselves and patients (2), and 
because locally recurring tumors or secondary gastric cancer 
after a gastrectomy can be cured by surgical resection in 
up to 80% of cases with early detection. In such cases, 
even if the recurrent tumor is beyond the curable stage by 
surgery, patients may receive chemotherapy or participate 
in clinical trials for newly developed drugs as early as 
possible (4, 21). However, there is a lack of evidence that 
postoperative imaging follow-up extends patient survival, 
and therefore, the risks of cumulative radiation exposure 
must be considered in balance with the anticipated benefits 
of recurrent imaging at the level of the individual patient 
(7).
A previous nationwide multicenter survey investigating 
Table 4. Lifetime Attributable Risk (LAR) of Cancer by CT and PET/CT Examination
LAR of Cancer Incidence (IQR) P Value LAR of Cancer Mortality (IQR) P Value
Total (n = 638) 0.28% (0.20-0.40) 0.18% (0.14-0.26)
EGC (n = 400) 0.26% (0.19-0.36) < 0.001 0.17% (0.13-0.23) < 0.001
AGC (n = 238) 0.33% (0.21-0.56) 0.21% (0.15-0.35)
Stage I (n = 445) 0.26% (0.19-0.37) 0.015* 0.17% (0.13-0.23) < 0.001
†
Stage II (n = 101) 0.28% (0.20-0.50) 0.19% (0.14-0.32)
Stage III (n = 92) 0.41% (0.26-0.69) 0.27% (0.17-0.46)
Note.— *Mann-Whitney U-test with Bonferroni correction: between stage I and II, p < 0.001; between stage II and III, p = 0.003; 
and between stage I and III, p < 0.001, 
†Mann-Whitney U-test with Bonferroni correction: between stage I and II, p < 0.001; 
between stage II and III, p < 0.001 and between stage I and III, p < 0.001. IQR = interquartile rangeKorean J Radiol 13(2), Mar/Apr 2012 kjronline.org 150
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current follow-up practices after curative resection of 
gastric cancer showed that CT is the most popular follow-up 
imaging method (88.5% of responders), followed by PET/
CT (60.4%) (4). This may be because CT is more objective 
and provides better diagnostic accuracy than ultrasound, 
including diagnosis of peritoneal recurrence (2, 4). Recently, 
PET/CT has become more widely used because it can 
diagnose small recurrent masses or peritoneal recurrence 
that may remain undetected by CT (2, 4). However, PET/CT 
studies also use ionizing radiation to generate images, and 
according to Brix et al. (11), the average effective dose of 
PET/CT is estimated to be 25 mSv (23.7-26.4 mSv), which is 
no less than that of CT studies. However, unlike CT or PET/
CT, ultrasound or magnetic resonance (MR) imaging does 
not generate ionizing radiation. Since contrast-enhanced 
ultrasound and MR have limited diagnostic performance 
for detecting peritoneal recurrence or deep-seated lymph 
node recurrence, ultrasound and liver MR are not used 
as sole imaging modalities for postoperative follow-up. 
However, in a limited set of patients with TNM stage I 
or EGC, ultrasound and MR could be used as alternative 
follow-up imaging modalities combined with CT, especially 
2-3 years after surgery because over two-thirds of tumor 
recurrence after surgery occurs in the first 2-3 years, and 
less than 10% recur after 5 years. If ultrasound and MR 
were to be used as alternative follow-up imaging modalities 
in conjunction with CT, the cED for patients with expected 
long-term survival could be reduced.
There are several limitations to our study. First, we 
assessed the estimated radiation induced lifetime cancer 
risk using the BEIR VII model, which is based on a linear 
non-threshold dose-response curve. Although recent 
reports from the National Research Council (BEIR VII) and 
International Commission on Radiological Protection have 
supported the appropriateness of the use of the linear non-
threshold model, there is still possibility that other models 
might be more appropriate for evaluating LAR for radiation-
induced cancer incidence and mortality (22).
Second, the BEIR VII model is based on general 
population data from the United States, whereas our study 
included patients with gastric cancer. As a result, the 
predicted LAR in our study may have been overestimated; 
in particular for patients with AGC, because they may have 
a shorter life expectancy compared to an age- and gender-
matched population.  
Third, there were statistical uncertainties when estimating 
cED and LAR in our study, because these values are 
calculated from DLP values, which are measured based on 
the absorbed dose to an acrylic phantom, and the different 
scanner models can result in some variability in DLP values 
(23). 
Fourth, the conversion factors vary according to not only 
the types of CT scanners or phantoms used to calculate the 
conversion factor, but also age, sex, tube voltage, and ICRP-
recommended tissue-weighting factors for the conversion 
factors, used to determine the effective dose from the DLP 
(5, 24). However, the most recent studies used published 
conversion factors and our results could show approximate 
values and the tendencies of radiation exposure to patients 
who underwent regular follow-ups after gastric surgery (10). 
Fifth, the cED might be underestimated because we 
did not include data from before each operation, such as 
preoperative imaging studies, as well as other diagnostic 
or therapeutic imaging studies such as interventional 
radiology, fluoroscopy, and radiography. 
Finally, the follow-up period in this study was relatively 
short. A future study with a longer duration of follow-up is 
warranted. 
In conclusion, the median cumulative dose of radiation 
increases according to gastric cancer stage and is much 
higher, even in patients with EGC or stage I gastric cancer 
than among the general population. Considering the 
good prognosis of EGC after curative surgery, cED should 
be considered as an important factor when designing 
postoperative follow-up protocols. 
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